Chitosan for biomedical applications, promising antidiabetic drug delivery system, and new diabetes mellitus treatment based on stem cell

Int J Biol Macromol. 2021 Nov 1:190:417-432. doi: 10.1016/j.ijbiomac.2021.08.154. Epub 2021 Aug 24.

Abstract

Since chitosan's excellent pharmacokinetic and chemical properties, it is an attractive and promising carbohydrate biopolymer in biomedical applications. Chitosan's beneficial function in the defense and propagation of pancreatic β cells, reducing hyperglycemia, and avoiding diabetes mellitus associated with impaired lipid metabolism has been demonstrated in several studies. Additionally, chitosan has also been used in various nanocarriers to deliver various antidiabetic drugs to reduce glucose levels. Herein, the first to provide the currently available potential benefits of chitosan in diabetes mellitus treatment focuses on chitosan-based nanocarriers for oral administration of various antidiabetic drugs nasal and subcutaneous passages. Moreover, chitosan is used to activate and deliver stem cells and differentiate them into cells similar to pancreatic beta cells as a new type of treatment for type one diabetes mellitus. The results of this review will be helpful in the development of promising treatments and better control of diabetes mellitus.

Keywords: Chitosan; Diabetes mellitus; Hyperglycemia; Stem cells.

Publication types

  • Review

MeSH terms

  • Biomedical Technology*
  • Chitosan / chemistry*
  • Diabetes Mellitus / drug therapy*
  • Drug Delivery Systems*
  • Glucose / metabolism
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Hypoglycemic Agents / therapeutic use*
  • Stem Cells / cytology*

Substances

  • Hypoglycemic Agents
  • Chitosan
  • Glucose